Sarepta Therapeutics Inc. (SRPT) CEO Edward M. Md Kaye Sells 40,179 Shares of Stock
Sarepta Therapeutics Inc. (NASDAQ:SRPT) CEO Edward M. Md Kaye sold 40,179 shares of Sarepta Therapeutics stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total value of $2,410,740.00. Following the sale, the chief executive officer now directly owns 117,162 shares of the company’s stock, valued at approximately $7,029,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) opened at 59.10 on Wednesday. Sarepta Therapeutics Inc. has a 52-week low of $8.00 and a 52-week high of $61.60. The company has a 50-day moving average price of $32.78 and a 200 day moving average price of $22.96. The company’s market capitalization is $2.83 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the prior year, the business posted ($0.87) EPS. Equities research analysts anticipate that Sarepta Therapeutics Inc. will post ($4.17) earnings per share for the current year.
Several equities research analysts have issued reports on SRPT shares. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target (up previously from $14.00) on shares of Sarepta Therapeutics in a research note on Wednesday, June 1st. Vetr raised Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price target for the company in a research note on Thursday, June 2nd. Jefferies Group reaffirmed a “sell” rating and set a $7.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, June 2nd. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $60.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. Finally, JMP Securities reissued a “sell” rating and issued a $10.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $48.70.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock worth $59,227,000 after buying an additional 161,790 shares in the last quarter. State Street Corp increased its position in shares of Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock worth $58,976,000 after buying an additional 625,051 shares during the period. BlackRock Fund Advisors increased its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock worth $20,865,000 after buying an additional 25,799 shares during the period. Finally, Franklin Resources Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter worth $13,506,000. Institutional investors own 72.09% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.